GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical firm, immediately introduced that the Company will probably be presenting at two upcoming scientific conferences in November 2022:
- American Heart Association Scientific Sessions 2022, Chicago, IL
Saturday, November 5, 2022
Poster Presentation at 11:00 am Central Time
Title: Effect of Pemvidutide (ALT-801), a Novel GLP-1/Glucagon Dual Receptor Agonist, on Pathogenic Lipid Mediators
Lead Author: Jorge Plutzky, MD, Director, Preventive Cardiology, Brigham and Women’s Hospital
- American Association for the Study of Liver Disease, The Liver Meeting®, Washington, DC
Monday, November 7, 2022
Poster Presentation at 1:00 pm Eastern Time
Title: Effects of a Balanced GLP-1/Glucagon Receptor Dual Agonist on Reduction of Liver Fat and Weight Loss: Results of a Phase 1b Multicenter, Randomized, Double-blind, Placebo-controlled Trial in Patients with Non-alcoholic Fatty Liver Disease
Lead Author: Stephen A. Harrison, MD, Medical Director, Pinnacle Research
A replica of the presentation supplies will probably be accessible on the Events part of the Altimmune web site.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical firm centered on the improvement of novel peptide-based therapeutics for the therapy of weight problems and liver ailments. The firm’s lead product candidate, pemvidutide, is a GLP-1/glucagon twin receptor agonist that’s being developed for the therapy of weight problems and non-alcoholic steatohepatitis (NASH). In addition, Altimmune is growing HepTcell™, an immunotherapeutic designed to obtain a practical remedy for persistent hepatitis B. For extra info, please go to www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Altimmune Investor & Media Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
[email protected]
